This Week in Cancer Discovery

Premium

In Cancer Discovery, researchers in the US and Australia report that pre-existing MEK1 exon 3 mutations in V600E/KBRAF melanomas don't confer resistance to BRAF inhibitors. The team sequenced MEK1/2 exon 3 in 31 melanomas at disease diagnosis and at progression, and found that five of them carried concurrent somatic BRAF/MEK1 activating mutations. Three of those five patients showed objective responses to BRAF inhibitors, consistent with the overall response rate to these drugs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.